BriaCell Reports Positive OS in Metastatic Breast Cancer

BriaCell Therapeutics Corp., a clinical-stage biotechnology company, has announced promising results from its Phase 2 clinical study involving Bria-IMT™ combined with an immune checkpoint inhibitor for treating late-stage metastatic breast cancer. The median overall survival (OS) for the most recent patients treated since 2022 was reported as 15.6 months. This is a significant improvement compared to the 6.7-9.3 months OS reported for similar patients in the literature.

Patients in the study were treated with the same Bria-IMT™ formulation currently being utilized in BriaCell’s ongoing Phase 3 pivotal study for metastatic breast cancer. The data also signify a substantial improvement over BriaCell’s previously reported median OS of 13.4 months in December 2023.

Dr. Sara A. Hurvitz, a Professor of Medicine at the Fred Hutch Cancer Center and University of Washington, who also serves on BriaCell’s medical advisory board, highlighted the poor prognosis for heavily pre-treated metastatic breast cancer patients and noted the encouraging data from the BriaCell study in terms of both efficacy and tolerability. Dr. William V. Williams, BriaCell’s President and CEO, emphasized the nearly two-fold improvement in overall survival observed with the Bria-IMT™ regimen compared to literature controls, which also showed an approximate doubling of progression-free survival.

Dr. Williams expressed optimism about the potential impact of Bria-IMT™ on the lives of heavily pre-treated metastatic breast cancer patients and the prospect of establishing it as a new standard of care. The ongoing Phase 3 study aims to further validate these findings.

Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer, remarked on the notable survival benefits seen with the Bria-IMT™ regimen, even in patients who had failed numerous prior treatments, including immune checkpoint inhibitors and antibody-drug conjugates. These findings support BriaCell’s hypothesis of additive and/or synergistic effects when combining immune checkpoint inhibitors with Bria-IMT™.

The Phase 2 study involved 54 heavily pre-treated metastatic breast cancer patients who were administered the Bria-IMT™ regimen along with an immune checkpoint inhibitor. Among these, 37 patients received the Phase 3 formulation, and 25 of these were treated after the resumption of full study activities post-COVID.

The data presented includes an additional six months of follow-up survival data compared to what was shown at the San Antonio Breast Cancer Symposium in December 2023. The comparative median overall survival and progression-free survival data for patients treated with the Bria-IMT™ formulation since 2022 are 15.6 months and 4.1 months, respectively.

BriaCell Therapeutics Corp. is dedicated to developing novel immunotherapies to transform cancer care. The company’s recent findings provide a strong rationale for the continued clinical development of Bria-IMT™ and its potential to become a new standard of care for metastatic breast cancer patients.